4 big analyst picks: Alcon upgraded to Outperform after Q1 beat | Pro Recap
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday.
Alcon upgraded to Outperform following Q1 beat
Baird upgraded Alcon (NYSE:ALC) to Outperform from Neutral and raised its price target to $90.00 from $75.00 following Q1 earnings.
As always, InvestingPro subscribers got this news first. Start your free 7-day trial to get on board.
Shares jumped more than 7% pre-market today after the company reported its Q1 results, with EPS of $0.70 and revenue of $2.3 billion beating the consensus estimates.
Neogenomics upgraded to Buy, shares jump on Q1 beat
BTIG upgraded NeoGenomics (NASDAQ:NEO) to Buy from Neutral with a price target of $25.00, noting it was impressed by the change in underlying growth at the company since the new management team has taken over.
Shares jumped more than 18% yesterday after the company delivered a strong Q1 beat and raised its full-year guidance.
BTIG said it was positively surprised both by the organic volume (up 7%) and pricing (up 8%) in the core lab services business in Q1, and expects the company to start benefiting from its recent launch of RaDaR MRD in the clinic, as well as Neo Comprehensive, in the clinic in Q2.
2 more upgrades
Enact (NASDAQ:ACT) shares closed more than 2% higher yesterday after BofA Securities upgraded the company to Neutral from Underperform and raised its price target to $27.00 from $25.00. Shares rose more than 2% yesterday.
The company reported its Q1 earnings last week, beating the Street estimates. Earlier this month, the company hiked its dividend by 14% to $0.16.
Piper Sandler upgraded Halozyme Therapeutics (NASDAQ:HALO) to Overweight from Neutral with a price target of $46.00.
Shares surged more than 5% yesterday after the company reported better-than-expected Q1 EPS, while revenues missed expectations.
Related Articles
4 big analyst picks: Alcon upgraded to Outperform after Q1 beat | Pro Recap
Lithium chemical firms Allkem and Livent to merge to create $10.6 billion group
Pharma CEOs to testify in U.S. Senate hearing on insulin prices
